RxDoctor Payments Data

Mark Jabro, MD

Internal Medicine · San Diego, CANPI 1326058330

Payments from drug & device makers

$58,946in general payments, 2019–2025

Across 223 payments — averaging $264.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$42K
  • Novo Nordisk$7K
  • Eli Lilly$6K
  • Vivus LLC$3K
  • Rhythm Pharmaceuticals, Inc.$395
  • Currax Pharmaceuticals LLC$334
  • plus $276 from 3 others

What the payments were for

  • Consulting fees$17,58330%
  • Speaking & faculty fees$28,00048%
  • Travel & lodging$8,60715%
  • Food & beverage$4,6308%
  • Education$1270%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,946 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$28,845
Medicare patients
109
Services billed
1,457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$97,758
JardianceEmpagliflozin76$96,744
EliquisApixaban46$56,682
MounjaroTirzepatide40$41,256
RybelsusSemaglutide18$34,765
JanuviaSitagliptin Phosphate14$22,538
XareltoRivaroxaban14$20,758
FarxigaDapagliflozin Propanediol15$19,142
WegovySemaglutide14$18,202
Humulin R U-500 KwikpenInsulin Regular, Human12$11,722
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$6,107
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$5,311
Olmesartan Medoxomil71$5,187
Rosuvastatin Calcium132$4,824
AbrysvoRsv Vacc, Pref A And Pref B/Pf15$4,510

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$6,648$150,725122 claims
Lilly USA, LLCMounjaro$42,380$41,25640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →